Less than $10/month! Screen on your Watchlists and Portfolios with Barchart Plus. FREE 30 Day Trial
or

Novo Nordisk A/S ADR (NVO)

Novo Nordisk A/S ADR (NVO)
78.11 -0.84 (-1.06%) 03/11/25 [NYSE]
74.27 x 200 74.30 x 300
Realtime by (Cboe BZX)
74.27 x 200 74.30 x 300
Realtime 74.30 -3.81 (-4.88%) 07:40 ET
Quote Overview for Tue, Mar 11th, 2025
Watch
    Add or delete the symbol from one or more Watchlists.
Day Low
77.00
Day High
79.27
Open 78.88
Previous Close 78.95 78.95
Volume 7,433,400 7,433,400
Avg Vol 7,900,035 7,900,035
Stochastic %K 19.59% 19.59%
Weighted Alpha -46.26 -46.26
5-Day Change -9.39 (-10.73%) -9.39 (-10.73%)
52-Week Range 77.00 - 148.15 77.00 - 148.15
  • 1D
  • 5D
  • 1M
  • 3M
  • 6M
  • 1Y
  • 5Y
  • MAX
Full Chart
  • OHLC Bars
  • Colored OHLC Bars
  • HLC Bars
  • Candlestick Hollow
  • Candlestick Open-to-Close
  • Candlestick Close-to-Close
  • Heikin-Ashi
  • Line Chart
  • Area Chart
  • Renko
  • Column
  • Baseline
  • Line Break
  • Range
  • Kagi
  • Point And Figure
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 350,521,152
  • Shares Outstanding, K 4,487,532
  • Annual Sales, $ 42,108 M
  • Annual Income, $ 14,643 M
  • EBIT $ 18,609 M
  • EBITDA $ 21,380 M
  • 60-Month Beta 0.42
  • Price/Sales 8.41
  • Price/Cash Flow 22.46
  • Price/Book 18.80

Options Overview Details

View History
  • Implied Volatility 42.93% ( -1.18%)
  • Historical Volatility 46.87%
  • IV Percentile 82%
  • IV Rank 55.08%
  • IV High 58.88% on 12/19/24
  • IV Low 23.37% on 06/12/24
  • Put/Call Vol Ratio 0.73
  • Today's Volume 25,887
  • Volume Avg (30-Day) 38,147
  • Put/Call OI Ratio 0.67
  • Today's Open Interest 399,419
  • Open Int (30-Day) 376,636

Analyst Rating / Earnings Estimates

Current Rating
See More
Moderate Buy
Based on 16 analysts offering recommendations.
Earnings Estimates - Current Qtr 03/31/25
See More
  • Average Estimate 0.96
  • Number of Estimates 3
  • High Estimate 1.00
  • Low Estimate 0.90
  • Prior Year 0.83
  • Growth Rate Est. (year over year) +15.66%

Price Performance

See More
Period Period Low Period High Performance
1-Month
77.00 +1.44%
on 03/11/25
Period Open: 83.74
93.80 -16.73%
on 02/25/25
-5.63 (-6.72%)
since 02/11/25
3-Month
77.00 +1.44%
on 03/11/25
Period Open: 111.69
111.17 -29.74%
on 12/12/24
-33.58 (-30.07%)
since 12/11/24
52-Week
77.00 +1.44%
on 03/11/25
Period Open: 131.24
148.15 -47.28%
on 06/25/24
-53.13 (-40.48%)
since 03/11/24

Most Recent Stories

More News
Why Hims & Hers Health Stock Just Popped

Roller-coaster healthcare stock Hims & Hers Health (NYSE: HIMS), whose stock got devastated last week by worries that it would be shut out of the GLP-1 market, got a reprieve from the Food and Drug Administration...

HIMS : 34.71 (+0.70%)
NVO : 78.11 (-1.06%)
LLY : 824.06 (-0.69%)
These 2 Vanguard ETFs Are Crushing the S&P 500 in 2025. Should You Buy?

After more than two years of a bull market run, the broader benchmark S&P 500 (SNPINDEX: ^GSPC) is starting to show some cracks. The index has given up all its post-election gains and finished Monday's...

SONY : 22.95 (+0.44%)
NVO : 78.11 (-1.06%)
$SPX : 5,572.07 (-0.76%)
RY : 110.33 (-2.35%)
NVS : 111.35 (-3.57%)
HSBC : 55.48 (-0.45%)
MUFG : 12.76 (+0.31%)
NSRGY : 100.9400 (-1.46%)
HTHIY : 24.3600 (-0.33%)
CBA.AX : 144.800 (-1.44%)
VYMI : 73.57 (-0.37%)
SHEL : 66.81 (+0.03%)
Hims & Hers Stock Is Down 50% From Its High, but Is This a Buying Opportunity?

Shutting down an acquisition caught investor attention, but there's more to the story.

HIMS : 34.71 (+0.70%)
NVO : 78.11 (-1.06%)
LLY : 824.06 (-0.69%)
Is Eli Lilly Stock a Buy?

Like many pharma stocks, Eli Lilly (NYSE: LLY) offers investors a bit of safety -- and it's an element you can count on during any economic environment. This is because patients need their medicines and...

VKTX : 26.52 (-5.15%)
NVO : 78.11 (-1.06%)
MS : 112.04 (+0.31%)
LLY : 824.06 (-0.69%)
AMGN : 318.89 (-2.59%)
The State of Weight Loss Drugs

In this podcast, Motley Fool analyst Karl Thiel joins host Ricky Mulvey to check in on the GLP-1 landscape. They discuss:

GIS : 62.33 (-4.55%)
VKTX : 26.52 (-5.15%)
NVO : 78.11 (-1.06%)
HIMS : 34.71 (+0.70%)
LLY : 824.06 (-0.69%)
CAG : 26.71 (-3.29%)
GPCR : 20.53 (+1.84%)
ISRG : 493.72 (+2.30%)
PFE : 25.99 (-2.44%)
Why Novo Nordisk Stock Is Falling Today

Shares of Novo Nordisk (NYSE: NVO) are tumbling on Monday. The company's stock lost 8.9% as of 10:10 a.m. ET and was down as much as 9.2% earlier in the day. The drop comes as the S&P 500 (SNPINDEX: ^GSPC)...

COMP : 8.54 (-0.35%)
$NASX : 17,436.10 (-0.18%)
NVO : 78.11 (-1.06%)
$SPX : 5,572.07 (-0.76%)
Despite Challenges Novo Nordisk Plans to Crush GLP-1 Competitors

Novo Nordisk slashed prices on its GLP-1 obesity drugs as it launches NovoCare to gain compounded GLP-1 users as the compounding labs face deadlines to cease.

NVO : 78.11 (-1.06%)
HIMS : 34.71 (+0.70%)
LLY : 824.06 (-0.69%)
3 Cold Stocks That Can Bounce Back This Week

These three stocks tumbled by at least 20% last week, but they may not be down for long.

VFC : 17.33 (-0.40%)
NVO : 78.11 (-1.06%)
HIMS : 34.71 (+0.70%)
LLY : 824.06 (-0.69%)
MRVL : 67.16 (+2.27%)
Pfizer Stock Up Almost 6% in 3 Months: Time to Buy, Sell or Hold?

Pfizer’s PFE stock has risen 5.9% in the past three months. The stock has started to show a consistent increase, with some ups and downs in between, after it took a hammering in the past couple of years...

NVO : 78.11 (-1.06%)
LLY : 824.06 (-0.69%)
ABBV : 213.59 (-1.42%)
PFE : 25.99 (-2.44%)
Pharma Stock Roundup: BAYRY's Q4 Results, ABBV's Obesity Deal & More

This week, Bayer BAYRY announced its fourth-quarter and full-year 2024 results. AbbVie ABBV announced a licensing deal with Danish firm Gubra for an amylin-targeting obesity treatment, which marked the...

BAYRY : 6.5000 (+1.56%)
NVO : 78.11 (-1.06%)
JNJ : 165.86 (-1.10%)
ABBV : 213.59 (-1.42%)
RHHBY : 42.0000 (-2.46%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 88% Sell with a Strengthening short term outlook on maintaining the current direction.

Long term indicators fully support a continuation of the trend.

The market is approaching oversold territory. Be watchful of a trend reversal.

See More Share

Business Summary

Bagsv'rd, Denmark-based Novo Nordisk is a global healthcare company and a leader in the worldwide diabetes market. The company is also a key player in hemophilia care, growth hormone therapy, hormone replacement therapy and obesity.Novo Nordisk operates through two segments: Diabetes and obesity care...

See More

Key Turning Points

3rd Resistance Point 81.52
2nd Resistance Point 80.40
1st Resistance Point 79.25
Last Price 78.11
1st Support Level 76.98
2nd Support Level 75.86
3rd Support Level 74.71

See More

52-Week High 148.15
Fibonacci 61.8% 120.97
Fibonacci 50% 112.58
Fibonacci 38.2% 104.18
Last Price 78.11
52-Week Low 77.00

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.
Free Barchart Webinar
How to Trade Futures Spreads Like a Pro – Unlock Powerful Market Insights